• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.97% Nasdaq Down1.18%

    Arena Pharmaceuticals, Inc. (ARNA)

    -NasdaqGS
    1.68 Down 0.03(1.55%) 12:31PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Arena Pharmaceuticals, Inc.
    6154 Nancy Ridge Drive
    San Diego, CA 92121
    United States - Map
    Phone: 858-453-7200
    Fax: 858-453-7210
    Website: http://www.arenapharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The company’s products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Undisclosed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Arena Pharmaceuticals, Inc.

    Corporate Governance 
    Arena Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Harry F. Hixson Jr., Ph.D., 77
    Chief Exec. Officer, Independent Director, Chairman of Science Committee and Member of Corp. Governance and Nominating Committee
    317.00K0.00
    Dr. Dominic P. Behan Ph.D., D.Sc., 52
    Co-Founder, Chief Scientific Officer, Exec. VP, Director and Member of Science Committee
    584.00K0.00
    Mr. Steven W. Spector J.D., 51
    Exec. VP, Gen. Counsel and Sec.
    554.00K248.00K
    Dr. William R. Shanahan Jr., M.D., J.D., 67
    Chief Medical Officer and Sr. VP
    521.00K200.00K
    Mr. Craig Michael Audet Ph.D., 52
    Head of Global Regulatory Affairs and Sr. VP of Operations
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders